NVS

Earnings Season Stats	Weekly Pharma Roundup: GSK Settles, Vivus Disappoints, Ely Lilly Axes	Hedge Fund East Coast on Consensus vs. Variant Perception Investing
Is Mannkind the Next Takeover Target?	China Biotech in Review: Pharma IPOs Raise $5.4 Billion in 12 Months	Pfizer Halts Trial of Pain Drug: Biotech's Latest Mishaps
Jury Still Out on Exelixis's Long Term Potential	New Challenges to Teva’s Business Model	Equity Income Stocks Rated Highly By S&P
Equity Income Stocks Rated Highly By S&P	Is Johnson & Johnson Really a Safety Stock?	Equities Update: Lower Finish After Soggy Economic Data
Jeremy Grantham Favors High Quality U.S. Stocks	Stocks With Increasing Dividends and Rising Revenue	Stocks Claw Back to End Day Lower, Week Higher
FDA Dislikes Novartis on Facebook: Biotech's Latest Mishaps	Synta Is Heating Up	Momenta Poised to Dominate $100B Blood Thinners Industry
Chelsea Could Benefit From FDA Proposition	China Orders Major Divestitures Before Novartis-Alcon Merger	The Economics of Drug Discovery: 'First in Class' vs. 'Best in Class'
China Biotech Week in Review: Upping the Stakes	Option Traders Position for Novartis Downside on FDA Drug Review	Just One Stock: Cash, Cost Savings in Undervalued Large-Cap Pharma

Main menu